Healthcare · Medical Devices
· website
· 226 employees
$3.52
52wk 1.00 – 3.53
Overall
54.0
Value
87.3
Growth
80.7
Health
0.0
Quality
0.0
Momentum
99.9
Dividend
—
Price
About AVITA Medical, Inc.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Price analytics
Returns
1 day
2.9%
1 week
6.0%
1 month
16.9%
3 months
145.3%
6 months
198.3%
1 year
112.0%
3 years
-1.4%
Risk
Volatility (1y ann.)
77.5%
Beta vs ASX 200
1.00
Sharpe (1y)
1.28
VaR 95% (1-day)
-5.1%
Max drawdown (1y)
-39.1%
Off 1-year high
0.0%
Technicals
RSI(14)
85
OB
vs 50DMA
39.0%
vs 200DMA
129.0%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value87.3
Trailing P/E
—
Forward P/E
100
PEG ratio
89
EV / EBITDA
100
Price / Book
100
Price / Sales
30
Growth80.7
Revenue growth (1y)
61
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow)0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum99.9
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
100
Position in 52-week range
100
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).